ATE353107T1 - Abhängigkeit des symptomfreien überlebens 5-fu behandelter darmkrebspatienten vom verhältnis der mrna-expressionshöhe aus thymidinphosphorylase und dihydropyrimidindehydrogenase - Google Patents
Abhängigkeit des symptomfreien überlebens 5-fu behandelter darmkrebspatienten vom verhältnis der mrna-expressionshöhe aus thymidinphosphorylase und dihydropyrimidindehydrogenaseInfo
- Publication number
- ATE353107T1 ATE353107T1 AT04020100T AT04020100T ATE353107T1 AT E353107 T1 ATE353107 T1 AT E353107T1 AT 04020100 T AT04020100 T AT 04020100T AT 04020100 T AT04020100 T AT 04020100T AT E353107 T1 ATE353107 T1 AT E353107T1
- Authority
- AT
- Austria
- Prior art keywords
- mrna expression
- ratio
- symptom
- dependence
- expression level
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03018783 | 2003-08-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE353107T1 true ATE353107T1 (de) | 2007-02-15 |
Family
ID=34259138
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04020100T ATE353107T1 (de) | 2003-08-28 | 2004-08-25 | Abhängigkeit des symptomfreien überlebens 5-fu behandelter darmkrebspatienten vom verhältnis der mrna-expressionshöhe aus thymidinphosphorylase und dihydropyrimidindehydrogenase |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20050100936A1 (de) |
| EP (1) | EP1510588B1 (de) |
| JP (1) | JP4032047B2 (de) |
| AT (1) | ATE353107T1 (de) |
| CA (1) | CA2479446C (de) |
| DE (1) | DE602004004571T2 (de) |
| ES (1) | ES2279266T3 (de) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1885878B1 (de) | 2005-05-31 | 2010-08-11 | Dako Denmark A/S | Zusammensetzungen und verfahren zur vorhersage des ausgangs einer behandlung |
| DE102006037158A1 (de) * | 2006-08-02 | 2008-02-14 | Bioxsys Gmbh | Verfahren zur Feststellung der Sensitivität von Tumoren gegenüber Capecitabin und Testkit |
| GB0900555D0 (en) * | 2009-01-14 | 2009-02-11 | Topotarget As | New methods |
| CN105699638B (zh) * | 2009-10-30 | 2018-05-22 | 学校法人庆应义塾 | 抗癌剂感受性的判定方法 |
| WO2011052748A1 (ja) * | 2009-10-30 | 2011-05-05 | 学校法人慶應義塾 | 抗がん剤の感受性判定方法 |
| JP2013531987A (ja) * | 2010-06-14 | 2013-08-15 | キアゲン ゲーエムベーハー | 固定生物学的試料から生体分子を抽出するためのターゲット細胞または組織を決定するための方法 |
| ES2393984B1 (es) * | 2011-02-24 | 2013-11-21 | Servicio Andaluz De Salud | Método de obtención de datos útiles para evaluar la respuesta al tratamiento con 5-fluorouracilo (5-FU) |
| EP3067698A1 (de) * | 2015-03-11 | 2016-09-14 | Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) | Pd-ecgf als biomarker für krebs |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19837391A1 (de) * | 1997-08-22 | 1999-02-25 | Hoffmann La Roche | Immunologische Materialien und Verfahren zum Nachweis von Dihydropyrimidindehydrogenase |
| US7005278B2 (en) * | 2001-03-02 | 2006-02-28 | Danenberg Kathleen D | Method of determining dihydropyrimidine dehydrogenase gene expression |
-
2004
- 2004-08-25 CA CA2479446A patent/CA2479446C/en active Active
- 2004-08-25 EP EP04020100A patent/EP1510588B1/de active Active
- 2004-08-25 ES ES04020100T patent/ES2279266T3/es active Active
- 2004-08-25 AT AT04020100T patent/ATE353107T1/de not_active IP Right Cessation
- 2004-08-25 DE DE602004004571T patent/DE602004004571T2/de active Active
- 2004-08-26 US US10/927,669 patent/US20050100936A1/en not_active Abandoned
- 2004-08-26 JP JP2004247413A patent/JP4032047B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| DE602004004571T2 (de) | 2007-11-08 |
| DE602004004571D1 (de) | 2007-03-22 |
| JP2005073698A (ja) | 2005-03-24 |
| EP1510588A1 (de) | 2005-03-02 |
| ES2279266T3 (es) | 2007-08-16 |
| EP1510588B1 (de) | 2007-01-31 |
| US20050100936A1 (en) | 2005-05-12 |
| JP4032047B2 (ja) | 2008-01-16 |
| CA2479446C (en) | 2013-05-07 |
| CA2479446A1 (en) | 2005-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE396731T1 (de) | Thiazole zur verwendung als inhibitoren von protein-kinasen | |
| DK1530724T3 (da) | Diagnose og forebyggelse af cancercelleinvasion | |
| TR200002784T2 (tr) | Tip 5 ve tip 3 17beta-Hidroksisteroid dehidrojenaz inhibitörleri ve bunların kullanımı için metodlar | |
| BRPI0410296A (pt) | sistema e método para a determinação da eficácia de tratamento de distúrbios neurológicos utilizando o eletroencefalograma | |
| WO2003035904A3 (en) | Methods and compositions to evaluate antibody treatment response | |
| ATE417639T1 (de) | Gerät zur bestimmung der dialyse-effizienz | |
| DE602004021838D1 (de) | Substituierte benzazole und ihre verwendung als raf-kinase-hemmer | |
| EA201000897A1 (ru) | Соединения и фармацевтические композиции для снижения уровня мочевой кислоты | |
| ATE553378T1 (de) | Screening und behandlungsverfahren zur vorbeugung von frühgeburten | |
| ATE450530T1 (de) | Zusammensetzungen zur verwendung als protein- kinase-inhibitoren | |
| DE60327999D1 (de) | Azolylaminoazine als inhibitoren von proteinkinasen | |
| NO20054744L (no) | Behandling av Alzheimers sykdom | |
| ATE540129T1 (de) | Target zur therapie kognitiver behinderungen | |
| ATE353107T1 (de) | Abhängigkeit des symptomfreien überlebens 5-fu behandelter darmkrebspatienten vom verhältnis der mrna-expressionshöhe aus thymidinphosphorylase und dihydropyrimidindehydrogenase | |
| HUP0303917A2 (hu) | Szterin abszorpció inhibitor(ok) kombinációi vérmódosítókkal és ezek alkalmazása vaszkuláris kondíciók kezelésére | |
| DE60324925D1 (de) | Ace2-aktivierung zur behandlung von herz, lungen, und nierenkrankheit und bluthochdruck | |
| ATE344049T1 (de) | Medikament, enthaltend cyanidin-3-glykosid als wirkstoff gegen fettsucht und diabetes | |
| DE60137635D1 (de) | Verwendung von allopurinol zur behandlung von bluthochdruck | |
| DE602005008639D1 (de) | Behandlung von entzündungen | |
| DE60234619D1 (de) | Gene und proteine für verhinderung, vorhersage, prognose und therapie der herzgefäss-krankheit | |
| DE602005018840D1 (de) | 3'-modifizierte oligonukleotide mit pseudoisocytosin-nukleobasenderivaten sowie deren anwendungen als primer oder sonden | |
| NO20053903D0 (no) | Nukleotidlipidesterderivater. | |
| SE0102147D0 (sv) | New methods | |
| WO2005005661A3 (en) | Genes regulated in ovarian cancer as prognostic and therapeutic targets | |
| EE200200087A (et) | Kompositsioon hepatotsellulaarse kartsinoomi raviks |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |